PharmaDrug’s Cepharanthine Shows Potential Against Monkeypox
Company Announcements

PharmaDrug’s Cepharanthine Shows Potential Against Monkeypox

Story Highlights

Pharmadrug (TSE:PHRX) has released an update.

PharmaDrug’s subsidiary Sairiyo Therapeutics has reported that cepharanthine, a component of their PD-001 drug, shows promise in binding to key proteins of the monkeypox virus, which could aid in the development of new treatments. The company is cautiously optimistic about PD-001’s potential as a multi-indication antiviral and is proceeding to Phase 1 clinical trials for its application in medical countermeasures and cancer, without claiming current efficacy in treating monkeypox.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Debenture Units Issuance Announcement
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Advances PD-001 for Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Begins Clinical Trial for Infectious Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App